16TH MILAN CONGRESS ON ANTICANCER INNOVATIVE THERAPY - 16TH EDITION

• FILIPPO DE BRAUD· PROFESSORE ORDINARIO
• MICHELE DEL VECCHIO· DIRIGENTE MEDICO
• MASSIMO DI NICOLA· DIRIGENTE MEDICO

• ANA MARIA ARANCE· RELATORE
• MATTEO MARIA BELLONE· RELATORE
• FILIPPO DE BRAUD· DOCENTE
• MICHELE DEL VECCHIO· DOCENTE
• MASSIMO DI NICOLA· DOCENTE
• GIANPIETRO DOTTI· MODERATORE
• WOLF HERMAN FRIDMAN· RELATORE
• LUCA GATTINONI· MODERATORE
• MASSIMO MASSAIA· MODERATORE
• SERENELLA PUPA· RELATORE
• FRANCESCA PUTTI· RELATORE
• MARCO RUELLA· RELATORE
• SARA TETTAMANTI· RELATORE
• ALBERTO ZAMBELLI· RELATORE

Ragione sociale

NADIREX INTERNATIONAL

Stato accreditamento

STANDARD - 1° rinnovo

Di sistema

In the last decade, adoptive cell therapies and in particular car t cells have dramatically changed the therapeutic landscape of hematological malignancies, providing hope where traditional treatments had failed. Their progressive expansion into the field of solid tumors confirms the extraordinary potential of cellular immunotherapy, yet also highlights the many challenges that still need to be addressed. Resistance to therapy, tumor escape mechanisms, the hostile microenvironment that limits t cell activity, and the persistence of treatment-related toxicities all represent major obstacles that must be overcome in order to fully realize the promise of these revolutionary strategies.

#1Applicazione nella pratica quotidiana dei principi e delle procedure dell'evidence based practice (EBM - EBN - EBP)

Area: Obiettivi formativi tecnico-professionali

Partecipanti max

100

Verifica presenza

Firma Di Presenza

Verifica apprendimento

Questionario A Risposta Multipla